BRITISH BIOTECH - HOW MUCH VALUE IS THERE IN METALLOPROTEINASE INHIBITORS

Authors
THOMAS SM FALKENHERR R BURKE JF
Citation
Sm. Thomas et al., BRITISH BIOTECH - HOW MUCH VALUE IS THERE IN METALLOPROTEINASE INHIBITORS, Expert opinion on therapeutic patents, 7(7), 1997, pp. 687-693
Citations number
3
Categorie Soggetti
Medicine, Legal","Pharmacology & Pharmacy
Journal title
Expert opinion on therapeutic patents → ACNP
ISSN journal
13543776
Volume
7
Issue
7
Year of publication
1997
Pages
687 - 693
Database
ISI
SICI code
1354-3776(1997)7:7<687:BB-HMV>2.0.ZU;2-K
Abstract
The value of British Biotech is built upon two matric: metalloproteina se (MMP) inhibitors, Marimastat and Batimastat, both in clinical trial s. These are supported by a strong patent portfolio in the area. A sec ond aspect of the company's activity is in the area of platelet activa ting factor (PAF) antagonists. Two genetically engineered proteins, a modified plasminogen thrombolytic and an inhibitor of stem cell prolif eration make up the pipeline.